{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:22:17Z","timestamp":1760984537174},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2_suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1998,8]]},"DOI":"10.1212\/wnl.51.2_suppl_2.s36","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:35:37Z","timestamp":1336916137000},"source":"Crossref","is-referenced-by-count":16,"title":["Management of response fluctuations"],"prefix":"10.1212","volume":"51","author":[{"given":"Ruth","family":"Djaldetti","sequence":"first","affiliation":[{"name":"From the Department of Neurology, Rabin Medical Center, Petah Tiqva, and the Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eldad","family":"Melamed","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Rabin Medical Center, Petah Tiqva, and the Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Fahn S. Fluctuation of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD Fahn S eds. Movement disorders. London: Butterworth Scientific 1982:123-145.","DOI":"10.1016\/B978-0-407-02295-9.50013-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198602000-00001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.1.1"},{"key":"e_1_3_2_6_2","first-page":"4","volume":"24","year":"1974","unstructured":"Fahn S. \"On-off\" phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431-441.","journal-title":"Neurology"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1979.00500420005001"},{"key":"e_1_3_2_8_2","first-page":"3","volume":"40","year":"1984","unstructured":"Ilson J, Fahn S, Cote L. Painful dystonic spasms in Parkinson's disease. Adv Neurol 1984;40:395-398.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_9_2","unstructured":"Duvoisin RC. Hyperkinetic reactions with L-dopa. In: Yahr MD ed. Current concepts in the treatment of parkinsonism. New York: Raven Press 1974:203-210."},{"key":"e_1_3_2_10_2","first-page":"1","volume":"52","year":"1977","unstructured":"Meunter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia (I-D-I and D-I-D) in response to L-dopa therapy of Parkinson's disease. Mayo Clin Proc 1977;52:163-174.","journal-title":"Mayo Clin Proc"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240103"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360703"},{"key":"e_1_3_2_13_2","first-page":"2","volume":"353","year":"1994","unstructured":"Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353:246-250.","journal-title":"FEBS Lett"},{"key":"e_1_3_2_14_2","first-page":"7","volume":"64","year":"1995","unstructured":"Ben-Shachar D, Zak R, Glinka Y. Dopamine neurotoxicity inhibition of mitochondrial respiration. J Neurochem 1995;64:718-723.","journal-title":"J Neurochem"},{"key":"e_1_3_2_15_2","first-page":"2","volume":"44","year":"1987","unstructured":"Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987;44:270-272.","journal-title":"Arch Neurol"},{"key":"e_1_3_2_16_2","first-page":"1","volume":"85","year":"1990","unstructured":"Bozeman T, Anuras S, Hutton T, Ghandour E, Mikeska C. Abnormal motility of the gastrointestinal tract in Parkinson's disease[Abstract]. Am J Gastroenterol 1990;85:1264.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_17_2","first-page":"7","volume":"42","year":"1992","unstructured":"Edwards LE, Pfeiffer RF, Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease. Frequency and pathophysiology. Neurology 1992;42:726-732.","journal-title":"Neurology"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.1"},{"key":"e_1_3_2_19_2","first-page":"1","volume":"38","year":"1988","unstructured":"Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.","journal-title":"Does levodopa aggravate Parkinson's disease? Neurology"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.1"},{"key":"e_1_3_2_22_2","first-page":"6","volume":"20","year":"1997","unstructured":"Gimenez-Roldan S, Tolosa E, Burguera JA, Chacon J, Liano H, Forcadell F. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997;20:67-76.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_23_2","first-page":"6","volume":"103","year":"1996","unstructured":"Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neurol Transm [Gen Sect] 1996;103:699-715.","journal-title":"J Neurol Transm [Gen Sect]"},{"key":"e_1_3_2_24_2","unstructured":"Hutton JH Moris JL. Long-acting levodopa preparations. In: Koller WC Paulson GW eds. Therapy of Parkinson's disease. New York: Marcel Dekker 1990:205-221."},{"key":"e_1_3_2_25_2","unstructured":"Rodnitzky RL. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Neurology 1992;42(Suppl 1):44-50."},{"key":"e_1_3_2_26_2","first-page":"6","volume":"43","year":"1993","unstructured":"Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa\/levodopa in Parkinson's disease. Neurology 1993;43:677-681.","journal-title":"Neurology"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Erni W Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987;27(Suppl 1):21-27.","DOI":"10.1159\/000116171"},{"key":"e_1_3_2_28_2","unstructured":"Yeh KC August TF Bush DF et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(Suppl 2):25-38."},{"key":"e_1_3_2_29_2","first-page":"3","volume":"14","year":"1991","unstructured":"Wilding IR, Hardy JG, Davis SS, et al. Characterization of the in vivo behaviour of a controlled-release formulation of levodopa(Sinemet CR). Clin Neuropharmacol 1991;14:305-321.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Rondot P Ziegler M Aymard N Holzer G. Clinical trial of madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy. Eur Neurol 1987;27(Suppl 1):105-113.","DOI":"10.1159\/000116205"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Nordera GP Lorizio A Lion P Durisotti C D'Andrea G Ferro-Milone F. Treatment of parkinsonian conditions with a controlled-release form of levodopa: preliminary study. Eur Neurol 1987;27(Suppl 1):76-80.","DOI":"10.1159\/000116197"},{"key":"e_1_3_2_32_2","first-page":"8","volume":"37","year":"1987","unstructured":"Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS. Parkinson's disease and motor fluctuations: long-acting carbidopa-levodopa(CR-4 Sinemet). Neurology 1987;37:875-878.","journal-title":"Neurology"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Siegfried J. Therapeutic value of madopar HBS: judgment after 2 years experience. Eur Neurol 1987;27(Suppl 1):98-104.","DOI":"10.1159\/000116203"},{"key":"e_1_3_2_34_2","first-page":"4","volume":"11","year":"1988","unstructured":"Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_35_2","first-page":"2","volume":"17","year":"1994","unstructured":"Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D-2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:286-293.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_36_2","unstructured":"Kreider M Knox S. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [Abstract]. Neurology 1996;46(Suppl):A475."},{"key":"e_1_3_2_37_2","first-page":"3","volume":"18","year":"1995","unstructured":"Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_38_2","first-page":"4","volume":"9","year":"1994","unstructured":"Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994;9:431-436.","journal-title":"Mov Disord"},{"key":"e_1_3_2_39_2","first-page":"8","volume":"48","year":"1997","unstructured":"Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87.","journal-title":"Neurology"},{"key":"e_1_3_2_40_2","first-page":"2","volume":"19","year":"1996","unstructured":"Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_41_2","first-page":"2","volume":"19","year":"1996","unstructured":"Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-233.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_42_2","first-page":"3","volume":"60","year":"1996","unstructured":"Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month double-blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_2_43_2","first-page":"4","volume":"71","year":"1985","unstructured":"Brodersen P, Philbert A, Gulliksen G, Stigard A. The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand 1985;71:494-497.","journal-title":"Acta Neurol Scand"},{"key":"e_1_3_2_44_2","first-page":"1","volume":"25","year":"1987","unstructured":"Golbe LI, Duvoisin RC. Double-blind trial of R-( -)-deprenyl for the \"on-off\" effect complicating Parkinson's disease. J Neural Transm Suppl 1987;25:123-129.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_2_45_2","first-page":"2","volume":"12","year":"1989","unstructured":"Friedman HG, Lannon MC. An open trial of controlled-release carbidopa\/L-dopa (Sinemet CR) for the treatment of mild-to-moderate Parkinson's disease. Clin Neuropharmacol 1989;12:220-223.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Quinn NP Marion MH Marsden CD. Open study of madopar HBS a new formulation of levodopa with benserazide in 13 patients with Parkinson's disease and \"on-off\" fluctuations. Eur Neurol 1987;27(Suppl 1):105-113.","DOI":"10.1159\/000116204"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_3_2_48_2","first-page":"1","volume":"43","year":"1993","unstructured":"Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa\/carbidopa in Parkinson's disease patients with \"on-off\" fluctuations. Neurology 1993;43:1698-1703.","journal-title":"Neurology"},{"key":"e_1_3_2_49_2","first-page":"4","volume":"41","year":"1991","unstructured":"Deleu D, Ebinger G, Michotte Y. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa\/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991;41:453-458.","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_3_2_50_2","first-page":"2","volume":"12","year":"1997","unstructured":"Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-292.","journal-title":"Mov Disord"},{"key":"e_1_3_2_51_2","first-page":"1","volume":"2","year":"1988","unstructured":"Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for \"on-off\" oscillations in Parkinson's disease. Lancet 1988;2:1260.","journal-title":"Lancet"},{"key":"e_1_3_2_52_2","first-page":"4","volume":"49","year":"1992","unstructured":"Van Laar T, Jansen EN, Essink AW, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992;49:482-484.","journal-title":"Arch Neurol"},{"key":"e_1_3_2_53_2","first-page":"4","volume":"1","year":"1988","unstructured":"Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-406.","journal-title":"Lancet"},{"key":"e_1_3_2_54_2","first-page":"1","volume":"43","year":"1993","unstructured":"Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa\/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993;43:1036-1039.","journal-title":"Neurology"},{"key":"e_1_3_2_55_2","first-page":"6","volume":"10","year":"1995","unstructured":"Neira WD, Sanchez V, Mena MA, de Yebenes JG. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995;10:66-70.","journal-title":"Mov Disord"},{"key":"e_1_3_2_56_2","first-page":"8","volume":"10","year":"1995","unstructured":"Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-84.","journal-title":"Mov Disord"},{"key":"e_1_3_2_57_2","first-page":"9","volume":"92","year":"1997","unstructured":"Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying and quality of life in patients with gastroparesis. Am J Gastroenterol 1997;92:976-980.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_58_2","first-page":"2","volume":"6","year":"1990","unstructured":"Vaamonde J, Luguin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord 1990;6:260-262.","journal-title":"Mov Disord"},{"key":"e_1_3_2_59_2","first-page":"2","volume":"96","year":"1993","unstructured":"Van Laar T, Jansen EN, Essink AW, Leef C, Oostreloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in \"off\" periods in Parkinson's disease. Clin Neurol Neurosurg 1993;96:231-235.","journal-title":"Clin Neurol Neurosurg"},{"key":"e_1_3_2_60_2","first-page":"5","volume":"15","year":"1992","unstructured":"Steiger MJ, Stocchi F, Bramante L, Ruggieri S, Quinn NP. The clinical efficacy of single morning doses of levodopa methylester, dispersible madopar and Sinemet plus in Parkinson's disease. Clin Neuropharmacol 1992;15:501-504.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00873695"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390103"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.1.1"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.12_Suppl_8.S7"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320101"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1996.6377"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.51.2_Suppl_2.S36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:21:38Z","timestamp":1711646498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.51.2_Suppl_2.S36"}},"subtitle":["Practical guidelines"],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":65,"journal-issue":{"issue":"2_suppl_2","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1212\/WNL.51.2_Suppl_2.S36"],"URL":"https:\/\/doi.org\/10.1212\/wnl.51.2_suppl_2.s36","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}